Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

The FDA has approved a first-of-its-kind treatment for dry age-related macular degeneration (AMD), a leading cause of blindness in adults over 55.

Citi has initiated coverage of EyePoint (EYPT) with a buy rating, stating it sees the company's drug Duravyu as well-positioned to compete in the wAMD market. Read more here.

Phase 1b clinical data underpins sozinibercept’s potential as a novel, first-in-class VEGF-C/D ‘trap’ to improve visual and anatomic outcomes in DME Published in peer-reviewed journal Translational ...

Macular degeneration is a leading cause of vision loss, especially in people over the age of 50. It affects the macula, a ...

SolidddVision smart glasses aim to restore vision for people living with macular degeneration, a condition that affects ...

Opyl has entered a joint venture with X Firm to market its TrialKey platform in key markets, while Dimerix has inked another ...

Essex Bio-Technology ( (HK:1061) ) has provided an announcement.

Toll-like receptors (TLRs) are vital components of the immune system, acting as sentinels that detect and respond to ...

CU-06 is under clinical development by Curacle and currently in Phase I for Ulcerative Colitis. According to GlobalData, Phase I drugs for Ulcerative Colitis have an 82% phase transition success rate ...

Reducing the risk of eye diseases involves a combination of lifestyle changes, protective measures and regular eye care ...

Since July 2024, faricimab has also been approved in Europe for the treatment of visual impairment due to macular edema ...